3 QUESTIONS ON . . . ‘Spillover’ Savings for the Oncology… : Oncology Times
An abstract is unavailable.
Related Articles
Atezolizumab combined with venetoclax and obinutuzumab for frontline CLL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential of combining atezolizumab, a humanized monoclonal anti–PD-L1 antibody,…
Performance of the WID‐qEC test to detect uterine cancers in black women with abnormal uterine bleeding: A prospective observational cohort study in Ghana
Endometrial cancer (EC) is increasing significantly among women in low- and middle-income countries (LMICs). EC detection may be improved by WID-qEC testing, a DNA methylation-based…
Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer
Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.
Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer
Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial.
The OncFive: Top Oncology Articles for the Week of 12/18
Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.
Ultra-Sensitive Duplex Sequencing Improves Diagnostic Capabilities in Indolent Systemic Mastocytosis
Tracy I. George, MD, discusses how ultra-sensitive duplex sequencing expands diagnostic capabilities in ISM by improving the detection of KIT mutations.
FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC
Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.
ctDNA, Neoadjuvant Immunotherapy Combos Could Help Reshape Management of CRC
Stacey A. Cohen, MD, provides an overview on the current landscape of immunotherapies and prognostic tools in the treatment of colorectal cancer.
Sharing AI insights without sharing patient data
The new Cancer AI Alliance includes Fred Hutch, Dana-Farber, Memorial Sloan Kettering, The Sidney Kimmel Comprehensive Cancer Center and the Whiting School of Engineering at…
